SAR exploration of the non-imidazole histamine H3 receptor ligand ZEL-H16 reveals potent inverse agonism

Arch Pharm (Weinheim). 2023 Jan;356(1):e2200451. doi: 10.1002/ardp.202200451. Epub 2022 Oct 30.

Abstract

Histamine H3 receptor (H3 R) agonists without an imidazole moiety remain very scarce. Of these, ZEL-H16 (1) has been reported previously as a high-affinity non-imidazole H3 R (partial) agonist. Our structure-activity relationship analysis using derivatives of 1 identified both basic moieties as key interaction motifs and the distance of these from the central core as a determinant for H3 R affinity. However, in spite of the reported H3 R (partial) agonism, in our hands, 1 acts as an inverse agonist for Gαi signaling in a CRE-luciferase reporter gene assay and using an H3 R conformational sensor. Inverse agonism was also observed for all of the synthesized derivatives of 1. Docking studies and molecular dynamics simulations suggest ionic interactions/hydrogen bonds to H3 R residues D1143.32 and E2065.46 as essential interaction points.

Keywords: G protein-coupled receptor (GPCR); agonism; histamine H3 receptor; inverse agonism; non-imidazole.

MeSH terms

  • Drug Inverse Agonism
  • Histamine Agonists / chemistry
  • Histamine Agonists / pharmacology
  • Histamine*
  • Ligands
  • Receptors, Histamine
  • Receptors, Histamine H3*
  • Structure-Activity Relationship

Substances

  • Histamine
  • ZEL-H16
  • Ligands
  • Histamine Agonists
  • Receptors, Histamine H3
  • Receptors, Histamine